Prostate Cancer
Conditions
Brief summary
This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are randomized upon objective progression (radiographic and/or clinical per PCWG2 criteria) to docetaxel/prednisone alone or the same combination plus enzalutamide. The primary aim is to evaluate whether continuing enzalutamide in combination with docetaxel in patients who failed or progressed while on enzalutamide would increase progression-free survival (PFS) by 4 months. The secondary end points are PSA responses, percent of patients alive at 1 and 2 years, decline in circulating tumor cells (CTCs), and quality of life (QOL) using validated scales.
Interventions
DRUGDocetaxel
DRUGEnzalutamide
DRUGPrednisone
Sponsors
University of Chicago
Astellas Pharma Inc
Prostate Cancer Clinical Trials Consortium
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information. NOTE: HIPAA authorization may be either included in the informed consent or obtained separately. * Males 18 years of age and above * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features * Having documented disease progression on enzalutamide defined by 1 or more of the following criteria: * PSA progression according to PCWG2 criteria with 3 consecutive rising PSA measurements, all collected at least 1 week apart * Radiographic progression in soft tissue or bone by modified RECIST 1.1 for subjects with measurable disease; or * Bone disease progression defined by 2 or more new lesions on 2 consecutive bone scans in the absence of falling PSA * Patients who have not had a bilateral orchiectomy must have a plan to maintain effective GnRG-analogue therapy for the duration of the trial * Serum testosterone level \< 50 ng/dL at Screening visit * ECOG PS: 0-1 * Throughout the study, male patients and their female partners of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following: * Condom (barrier method of contraception even if having sex with a pregnant woman) * One of the following is required: * Established use of oral, injected, or implanted hormonal method of contraception by the female partner * Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner * Additional barrier method: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner * Tubal litigation in the female partner * Vasectomy or other procedure resulting in infertility (eg, bilateral orchiectomy) for \>6 months * Patients must have adequate organ and marrow function as defined below * Leukocytes \>3,000/mm3 * absolute neutrophil count \>1,500/mm3 * platelets \>100,000/mm3 * total bilirubin within normal institutional limits (or \<2X the upper limit of normal in those with Gilbert's disease) * AST(SGOT)/ALT(SGPT) \<1.5 X institutional upper limit of normal * creatinine within normal institutional limits OR * creatinine clearance\* \>45 mL/min/1.73 m2 for patients with creatinine levels above institutional normal * Estimated life expectancy of \> 6 months * Able to swallow the study drug as prescribed and comply with study requirements
Exclusion criteria
* Prior treatment with docetaxel-based chemotherapy * Prior treatment with abiraterone acetate * Prior treatment with cabazitaxel * Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment * Ongoing investigational treatment * Medical conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus, cardiac disease that would, in the opinion of the investigator, make this protocol unreasonably hazardous * Major surgery within 4 weeks of enrollment * Use of an investigational therapeutic agent with 4 weeks of enrollment * History of seizure or any condition that may predispose to seizure. * History of loss of consciousness or transient ischemic attack within 12 months of enrollment * Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease) within last 3 months * Grade \> 2 treatment-related toxicity from prior therapy * History of hypersensitivity to polysorbate 80 * Any known allergy to the compounds under investigation * Any other condition which, in the opinion of the Investigator, would preclude participation in this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (Radiographic or Per PCWG2 Criteria) | 1 year | The primary endpoint of the study is progression-free survival (PFS), defined as the time from randomization to disease progression. Progression will be evaluated using a combination of RECIST and Prostate Cancer Working Group 2 guidelines. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PSA Response in the Standard Treatment Arm and Experimental Treatment Arm | Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231, and every 21 days through study completion (an average of 1 year) | PSA response measured according to Prostate Cancer Working Group 2 (PCWG2). The study was terminated after only 9 patients enrolled, 5 to the standard of care docetaxel/prednisone arm and 4 to experimental docetaxel/prednisone/enzalutamide arm. |
| Overall Survival | At both 1 year and 2 years from treatment start | — |
Other
| Measure | Time frame |
|---|---|
| Quality of Life (QOL) | Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231 and every 21 days through study completion (an average of 1 year) |
| Circulating Tumor Cells (CTCs) | Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year) |
| Analysis of Androgen Receptor Splice Variant | Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Docetaxel/Prednisone Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
Docetaxel
Prednisone | 5 |
| Docetaxel/Prednisone + Enzalutamide Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
Docetaxel
Enzalutamide
Prednisone | 4 |
| Total | 9 |
Baseline characteristics
| Characteristic | Docetaxel/Prednisone + Enzalutamide | Total | Docetaxel/Prednisone |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 5 Participants | 3 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 4 Participants | 2 Participants |
| Age, Continuous | 67.25 years | 67.78 years | 68.2 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 5 Participants | 3 Participants |
| Region of Enrollment United States | 4 participants | 9 participants | 5 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 4 Participants | 9 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 3 / 5 | 0 / 4 |
| other Total, other adverse events | 5 / 5 | 4 / 4 |
| serious Total, serious adverse events | 2 / 5 | 0 / 4 |
Outcome results
Primary
Progression-free Survival (Radiographic or Per PCWG2 Criteria)
The primary endpoint of the study is progression-free survival (PFS), defined as the time from randomization to disease progression. Progression will be evaluated using a combination of RECIST and Prostate Cancer Working Group 2 guidelines.
Time frame: 1 year
Population: As the study was terminated after only 9 patients enrolled, 5 to the standard of care docetaxel/prednisone arm and 4 to experimental docetaxel/prednisone/enzalutamide arm, the study was not evaluable for any efficacy endpoints.~Sufficient data for the primary endpoint were not collected to provide outcome measures data tables below.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Docetaxel/Prednisone | Progression-free Survival (Radiographic or Per PCWG2 Criteria) | 0 Participants |
| Docetaxel/Prednisone + Enzalutamide | Progression-free Survival (Radiographic or Per PCWG2 Criteria) | 0 Participants |
Comparison: The study was terminated after only 9 patients enrolled, 5 to the standard of care docetaxel/prednisone arm and 4 to experimental docetaxel/prednisone/enzalutamide arm.p-value: 0.6761Chi-squared
Secondary
Overall Survival
Time frame: At both 1 year and 2 years from treatment start
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Docetaxel/Prednisone | Overall Survival | 2 Participants |
| Docetaxel/Prednisone + Enzalutamide | Overall Survival | 4 Participants |
Secondary
PSA Response in the Standard Treatment Arm and Experimental Treatment Arm
PSA response measured according to Prostate Cancer Working Group 2 (PCWG2). The study was terminated after only 9 patients enrolled, 5 to the standard of care docetaxel/prednisone arm and 4 to experimental docetaxel/prednisone/enzalutamide arm.
Time frame: Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231, and every 21 days through study completion (an average of 1 year)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Docetaxel/Prednisone | PSA Response in the Standard Treatment Arm and Experimental Treatment Arm | 2 Participants |
| Docetaxel/Prednisone + Enzalutamide | PSA Response in the Standard Treatment Arm and Experimental Treatment Arm | 3 Participants |
Other Pre-specified
Analysis of Androgen Receptor Splice Variant
Time frame: Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year)
Other Pre-specified
Circulating Tumor Cells (CTCs)
Time frame: Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year)
Other Pre-specified
Quality of Life (QOL)
Time frame: Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231 and every 21 days through study completion (an average of 1 year)